At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 108 enrolled
Drug / intervention
Sitagliptindrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sitagliptin in Combination Oral Agent Therapy for Type 2 Diabetes
Charles Drew University of Medicine and Science·interventional·Posted May 30, 2008·Updated Nov 26, 2014
In Brief
A Phase 4 clinical trial evaluating Sitagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 108 participants across 1 site.
Detailed Summary
This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in comparison to thiazolidinediones as the third-line oral agent, in patients with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR)
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedMay 2008
Primary CompletionMar 2010
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartJan 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.1 years ago
Interventions
Sitagliptindrug
Sitagliptin 100 mg by mouth once daily